The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention, ...

Centre for Epidemiological Modelling and Analysis (CEMA), have released results of three studies that could significantly ...

A new study explores how healthcare providers can effectively implement Apretude for HIV pre-exposure prophylaxis (PrEP) ...

ViiV Healthcare has announced steps to widen access to a sought-after HIV medicine in low- and middle-income countries, ...

We’ve come a long way in treating HIV, the virus that can lead to AIDs. Just last month, the FDA approved a medication that ...

ViiV Healthcare, the HIV-focused joint venture majority owned by GSK , said on Monday it has expanded its licensing deal with ...

Lenacapavir offers twice-yearly HIV prevention with near-complete protection in clinical trials. Clinical trials show ...

Proposed Medicaid cuts could threaten lifesaving HIV treatment access, warns Avenue 360. HOUSTON — With President Trump's " ...

Aurobindo Pharma will manufacture and supply long-acting injectable HIV treatment, cabotegravir, across 133 countries through ...

The administration made a deal with Senate Republicans to remove $400 million in proposed cuts to the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR).

The third study, Twiga , is an ongoing five-year observational study tracking comorbidities in both HIV-positive and HIV-negative individuals aged 60 and above. It was initiated to better understand ...

Aurobindo Pharma to manufacture and supply long-acting injectable HIV treatment in 133 countries, offering alternative to ...